THCJD: what is this synthetic cannabinoid?

The name THCJD refers to a synthetic analogue of THC whose side chain — the part of the molecule that largely determines its affinity for cannabinoid receptors — has been lengthened in the laboratory. Natural THC has a five-carbon chain; analogues such as THCJD are built on a longer, eight-carbon chain, designed to alter the intensity of the effect sought. This chemical modification does not occur naturally in the hemp plant.

Unlike CBD, CBG or THCV, which are phytocannabinoids produced directly by the plant, THCJD is a laboratory creation. It is generally obtained by chemically modifying a base cannabinoid such as CBD, through a semi-synthesis process. This artificial origin brings it close, in regulatory and health terms, to the other semi-synthetic cannabinoids that appeared in France between 2022 and 2024, such as HHC or THCP.

Sellers of products containing THCJD emphasise a potency of effect markedly greater than that of conventional THC. To date, no toxicological or pharmacokinetic data published and validated by a health agency makes it possible to confirm these claims or to assess the risks associated with its consumption. The complete absence of any clinical trial, or even of any published preclinical study, is in itself a warning signal for any molecule in this family.

THCJD does not, to date, appear explicitly on the list of cannabinoids classified as narcotics by name by the ANSM. It nevertheless falls within the same logic as HHC, H4CBD or THCP — synthetic molecules mimicking the effect of THC, which the ANSM progressively prohibited between 2023 and 2024 as they appeared on the market. A product sold or marketed for its psychoactive effect, whatever the exact nomenclature of the molecule used, exposes both seller and buyer to significant legal risk under narcotics law.

The absence of an explicit regulatory framework does not mean the absence of risk, whether legal or health-related. The pace of prohibition observed since 2023 shows that the ANSM rapidly classifies as a narcotic any new synthetic cannabinoid identified on the French market. A compliant CBD product — full spectrum, broad spectrum or isolate — remains the best-documented and the safest option in regulatory terms. To understand the family of prohibited cannabinoids, see our guide to THC and the French framework.

Is THCJD sold in France?

It is not a common product on the compliant French CBD market. Any presence stems from channels that circumvent the regulations applicable to synthetic cannabinoids.

Is THCJD more dangerous than THC?

No validated scientific data makes it possible to confirm this with certainty, but the complete absence of any published safety study calls for great caution.

How can you recognise a product based on an unauthorised synthetic cannabinoid?

Always check the certificate of analysis from an independent laboratory, which must list the cannabinoids present. The absence of such transparency is in itself a warning signal.

Will THCJD one day be explicitly prohibited in France?

Nothing rules it out. Since 2023 the ANSM has demonstrated an ability to rapidly classify as a narcotic any new synthetic cannabinoid mimicking the effect of THC.